Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: August 31, 2023 Report Code: GDHC130CL-ST

Select Item

Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview

Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain ethnic groups, such as people who are Black, Mexican American, Polynesian, and Pima Indian.

The Diabetic Nephropathy (DN) marketed, and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for Diabetic Nephropathy (DN). The report also analyzes the clinical and commercial landscapes of DN, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Key Mechanism of Action (Marketed) ·       Enzyme Inhibitor

·       Receptor Antagonist

·       Transporter Inhibitor

·       Biological Factor Activator
Key Routes of Administration (Marketed) ·       Oral

·       Injection
Key Molecule Types (Marketed) ·       Small molecules

·       Biologics
Key Mechanisms of Action (Pipeline) ·       Receptor Antagonist

·       Biological Factor Inhibitor

·       Enzyme Inhibitor

·       Receptor Inhibitor

·       Receptor Agonist
Key Routes of Administration (Pipeline) ·       Oral

·       Injection

·       Enteral

·       Inhalational

·       Topical
Key Molecule Types (Pipeline) ·       Biologics

·       Small molecules

·       Oligonucleotides
Top Sponsors (Marketed and Pipeline Drugs) ·       Boehringer Ingelheim

·       Bayer AG

·       Mitsubishi Tanabe Pharma

·       Kashan University of Medical Sciences and Health Services

·       AstraZeneca Plc
Enquire & Decide ·       Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Leading Marketed Drugs in Diabetic Nephropathy (DN)

Canagliflozin, Hydrochlorothiazide, Kallidinogenase, Sulodexide, Irbesartan, and Losartan potassium are a few of the leading marketed drugs in Diabetic Nephropathy (DN). The pharmacological treatment of DN in the early stages mainly includes innovator products from the ACE inhibitor and ARB classes, such as BMS’s Capoten and Mitsubishi Tanabe Pharma’s Tanatril, among others, to manage blood pressure.

Diabetic Nephropathy (DN) Drugs Market – Competitive Landscape

A few of the top sponsors in the DN marketed and pipeline drugs market are the Boehringer Ingelheim, Bayer AG, Mitsubishi Tanabe Pharma, Kashan University of Medical Sciences and Health Services, and AstraZeneca Plc, among others. In 2023, the Boehringer Ingelheim leads among the trial sponsors after adding up all the trial phases.

Diabetic Nephropathy (DN) Market Analysis by Sponsors, 2023 (%)

Diabetic Nephropathy (DN) Market Analysis by Sponsors, 2023 (%)

Buy the Full Report for More Sponsor Insights into the DN Market Download a Free Report Sample

Diabetic Nephropathy (DN) Marketed Drugs Segmentation by Mechanisms of Action

Enzyme inhibitor, receptor antagonist, transporter inhibitor, and biological factor activator are the key MoA in DN-marketed drugs. In 2023, most of the marketed drugs for DN are enzyme inhibitor.

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

Buy the Full Report to Know More about the MoA of DN Marketed Drugs

Download a Free Report Sample

Diabetic Nephropathy (DN) Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for Diabetic Nephropathy (DN)marketed drugs are oral and injection. In 2023, most of the marketed drugs available for DN are oral drugs.

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Routes of Administration, 2023 (%)

Buy the Full Report to Know More about the RoA of Diabetic Nephropathy (DN) Marketed Drugs

Download a Free Report Sample

Diabetic Nephropathy (DN) Marketed Drugs Segmentation by Molecule Types

The key molecule types for Diabetic Nephropathy (DN) marketed drugs are biologics and small molecules. The small molecule is leading in the market in 2023.

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Molecule Types, 2023 (%)

Diabetic Nephropathy (DN) Marketed Drugs Analysis by Molecule Types, 2023 (%)

Buy the Full Report to Know More about the Molecule Types of Diabetic Nephropathy (DN) Marketed Drugs

Download a Free Report Sample

Diabetic Nephropathy (DN) Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action for Diabetic Nephropathy (DN) pipeline drugs are receptor antagonist, biological factor inhibitor, enzyme inhibitor, receptor inhibitor, and receptor agonist among others. In 2023, most of the drugs in the DN pipeline are receptor antagonist.

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

Buy the Full Report to Know More about the MoA of DN Pipeline Drugs

Download a Free Report Sample

Diabetic Nephropathy (DN) Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration for DN pipeline drugs are injection, oral, enteral, inhalational, and topical. Most pipeline drugs for DN are oral therapies.

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

Buy the Full Report to Know More about the RoA of Diabetic Nephropathy (DN) Pipeline Drugs

Download a Free Report Sample

DN Pipeline Drugs Market Segmentation by Molecule Types

Most of the pipeline drugs in the DN landscape are small molecules, followed by biologics. The key biologic drugs are tozorakimab and Orbcel-M among others. Oligonucleotides is another type of molecule type in the DN pipeline drugs market.

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)

Diabetic Nephropathy (DN) Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)

Buy the Full Report to Know More About the Molecule Types of Diabetic Nephropathy (DN) Pipeline Drugs

Download a Free Report Sample

Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Market Recent Deals

A few of the recent deals in the Diabetic Nephropathy (DN) marketed and pipeline drugs are:

  • Cantex Pharma enters into a licensing agreement with Georgetown University
  • Lubea Acquires 26% stake in ESTEVE (LABORATORIOS DEL DR ESTEVE SA, Esteve Pharmaceuticals)

Buy the Full Report to Know More About the Recent Deals of Diabetic Nephropathy (DN) Drugs Market

Download a Free Report Sample

Segments Covered in the Report

DN Marketed Drugs Mechanism of Action (Number of Drugs, 2023)

  • Enzyme Inhibitor
  • Receptor Antagonist
  • Transporter Inhibitor
  • Biological factor Activator

DN Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral

DN Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)

  • Biologics
  • Small molecules

DN Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

  • Receptor antagonist
  • Biological Factor Inhibitor
  • Enzyme Inhibitor
  • Receptor Inhibitor
  • Receptor Agonist

DN Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

  • Injection
  • Oral
  • Enteral
  • Inhalational
  • Topical

DN Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)

  • Biologics
  • Small molecules
  • Oligonucleotides

Scope

Components of the report include –

  • Disease Landscape

  • Disease Overview

  • Epidemiology Overview

  • Treatment Overview

  • Marketed Products Assessment

  • Breakdown by Mechanism of Action, Route of Administration

  • Product Profiles with Sales Forecast

  • Pricing and Reimbursement Assessment

  • Annual Therapy Cost

  • Time to Pricing and Time to Reimbursement

  • Pipeline Assessment

  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

  • Product Profiles with Sales Forecast

  • Late-to-mid-stage Pipeline Drugs

  • Phase Transition Success Rate and Likelihood of Approval

  • Clinical Trials Assessment

  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

  • Enrolment Analytics, Site Analytics, Feasibility Analysis

  • Deals Landscape

  • Mergers, Acquisitions, and Strategic Alliances by Region

  • Overview of Recent Deals

  • Commercial Assessment

  • Key Market Players

  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the DN market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DN market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface_x000D_

1.1 Contents_x000D_

1.2 Report Scope_x000D_

1.3 List of Tables and Figures_x000D_

1.4 Abbreviations_x000D_

2 Key Findings_x000D_

3 Disease Landscape_x000D_

3.1 Disease Overview_x000D_

3.2 Epidemiology Overview_x000D_

3.3 Treatment Overview _x000D_

4 Marketed Drugs Assessment_x000D_

4.1 Leading Marketed Drugs_x000D_

4.2 Overview by Mechanism of Action_x000D_

4.3 Overview by Route of Administration_x000D_

4.4 Marketed Drugs Profiles and Sales Forecasts_x000D_

5 Pricing and Reimbursement Assessment_x000D_

5.1 Annual Therapy Cost_x000D_

5.2 Time to Pricing and Reimbursement_x000D_

6 Pipeline Drugs Assessment_x000D_

6.1 Phase III Pipeline Drugs_x000D_

6.2 Overview by Development Stage_x000D_

6.3 Overview by Molecule Type_x000D_

6.4 Overview by Mechanism of Action_x000D_

6.5 Overview by Route of Administration_x000D_

6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)_x000D_

6.7 Therapy Area and Indication-specific PTSR and LoA_x000D_

7 Clinical Trials Assessment_x000D_

7.1 Historical Overview_x000D_

7.2 Overview by Phase_x000D_

7.3 Overview by Status_x000D_

7.4 Overview by Phase for Ongoing and Planned Trials_x000D_

7.5 Trials with Virtual Components_x000D_

7.6 Geographic Overview_x000D_

7.7 Single-Country and Multinational Trials by Region_x000D_

7.8 Top 20 Sponsors with Breakdown by Phase_x000D_

7.9 Top 20 Sponsors with Breakdown by Status_x000D_

7.10 Overview by Endpoint Status_x000D_

7.11 Overview by Race and Ethnicity_x000D_

7.12 Enrollment Data_x000D_

7.13 Top 20 countries for Trial Sites_x000D_

7.14 Top 20 Sites Globally_x000D_

7.15 Feasibility Analysis – Geographic Overview_x000D_

7.16 Feasibility Analysis – Benchmark Models_x000D_

8 Deals Landscape_x000D_

8.1 Mergers, Acquisitions, and Strategic Alliances by Region_x000D_

8.2 Recent Mergers, Acquisitions, and Strategic Alliances_x000D_

9 Commercial Assessment_x000D_

9.1 Key Market Players_x000D_

10 Future Market Catalysts_x000D_

11 Appendix_x000D_

11.1 Methodology_x000D_

11.2 Methodology – Sales Forecast_x000D_

11.3 Methodology – Pricing and Reimbursement_x000D_

11.4 Methodology – PTSR and LoA Analysis_x000D_

11.5 About the Authors_x000D_

11.6 Contact Us_x000D_

11.7 Disclaimer

Frequently asked questions

Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Diabetic Nephropathy reports
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more